X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (172) 172
hematology (166) 166
index medicus (162) 162
female (149) 149
adult (148) 148
male (147) 147
transplantation (145) 145
middle aged (141) 141
aged (106) 106
stem cells (106) 106
adolescent (104) 104
retrospective studies (100) 100
leukemia, myeloid, acute - therapy (81) 81
oncology (76) 76
young adult (76) 76
leukemia (72) 72
treatment outcome (71) 71
transplantation, homologous (68) 68
acute myeloid leukemia (67) 67
bone marrow (62) 62
versus-host-disease (59) 59
acute myeloid-leukemia (57) 57
survival (55) 55
hematopoietic stem cells (54) 54
stem cell transplantation (54) 54
leukemia, myeloid, acute - mortality (53) 53
hematopoietic stem cell transplantation - methods (51) 51
life sciences (51) 51
stem-cell transplantation (51) 51
disease-free survival (50) 50
remission (50) 50
transplantation conditioning - methods (49) 49
analysis (46) 46
bone-marrow-transplantation (46) 46
multivariate analysis (46) 46
remission induction (46) 46
adults (44) 44
prognosis (44) 44
hematopoietic stem cell transplantation (43) 43
mortality (43) 43
recurrence (43) 43
survival analysis (43) 43
myeloid leukemia (41) 41
research (40) 40
unrelated donors (40) 40
cancer (38) 38
survival rate (38) 38
graft vs host disease - etiology (37) 37
risk factors (37) 37
transplants & implants (37) 37
blood (35) 35
hematopoietic stem cell transplantation - adverse effects (35) 35
aml (34) 34
hematology, oncology and palliative medicine (34) 34
1st complete remission (32) 32
chemotherapy (32) 32
follow-up studies (32) 32
hematologic malignancies (32) 32
child (31) 31
patients (30) 30
graft-versus-host reaction (29) 29
transplantation conditioning (29) 29
abridged index medicus (28) 28
immunology (28) 28
precursor cell lymphoblastic leukemia-lymphoma - therapy (27) 27
acute myelogenous leukemia (26) 26
child, preschool (26) 26
health aspects (26) 26
hemic and lymphatic diseases (26) 26
incidence (26) 26
europe (25) 25
graft vs host disease - mortality (24) 24
hemopoiesis (24) 24
myelodysplastic syndrome (24) 24
reduced-intensity (24) 24
relapse (24) 24
acute disease (23) 23
bone marrow transplantation (23) 23
cyclophosphamide (23) 23
working party (23) 23
[sdv]life sciences [q-bio] (22) 22
acute lymphoblastic-leukemia (22) 22
bone-marrow (22) 22
graft vs host disease - prevention & control (22) 22
busulfan (21) 21
human health and pathology (21) 21
infant (21) 21
outcomes (21) 21
precursor cell lymphoblastic leukemia-lymphoma - mortality (21) 21
registries (21) 21
therapy (21) 21
transplantation, autologous (20) 20
acute leukemia (19) 19
allogeneic stem cell transplantation (19) 19
hematopoietic stem cell transplantation - mortality (19) 19
usage (19) 19
adult patients (18) 18
care and treatment (18) 18
children (18) 18
donors (18) 18
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Blood, ISSN 0006-4971, 11/2010, Volume 116, Issue 21, pp. 3556 - 3556
Abstract Abstract 3556 The prognosis of patients with AML harbouring the FlT3 ITD is known to be poor in patients treated with chemotherapy only. However it... 
Journal Article
Haematologica, ISSN 0390-6078, 02/2010, Volume 95, Issue 2, pp. 284 - 292
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2004, Volume 351, Issue 22, pp. 2276 - 2285
Journal Article
Cancer, ISSN 0008-543X, 04/2018, Volume 124, Issue 7, pp. 1428 - 1437
BACKGROUND Incidence of graft‐versus‐host disease (GVHD) in haploidentical bone marrow (BM) transplants using posttransplantion cyclophosphamide (PT‐Cy) is... 
stem cell source | acute graft‐versus‐host disease | haploidentical transplantation | posttransplantation cyclophosphamide | acute leukemia | acute graft-versus-host disease | SURVIVAL | ALTERNATIVE DONORS | INTENSITY | UNRELATED DONOR TRANSPLANTATION | ACUTE MYELOID-LEUKEMIA | VERSUS-HOST-DISEASE | ONCOLOGY | LEUKEMIA WORKING PARTY | OUTCOMES | HEMATOLOGIC MALIGNANCIES | REMISSION | Myeloablative Agonists - therapeutic use | Precursor Cell Lymphoblastic Leukemia-Lymphoma - immunology | Prognosis | Follow-Up Studies | Humans | Middle Aged | Male | Leukemia, Myeloid, Acute - immunology | Cyclophosphamide - therapeutic use | Young Adult | Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy | Graft vs Host Disease - mortality | Adult | Female | Retrospective Studies | Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology | Leukemia, Myeloid, Acute - therapy | Leukemia, Myeloid, Acute - pathology | Peripheral Blood Stem Cell Transplantation - mortality | Survival Rate | Combined Modality Therapy | Bone Marrow Transplantation - mortality | Adolescent | Graft vs Host Disease - prevention & control | Aged | Transplantation Conditioning | Transplantation, Haploidentical | Graft-versus-host reaction | Acute lymphatic leukemia | Transplants & implants | Myeloid leukemia | Leukemia | Bone marrow transplantation | Transplants | Transplantation | Lymphatic leukemia | Multivariate analysis | Patients | Survival | Blood | Hematopoietic stem cells | Incidence | Cyclophosphamide | Stem cells | Peripheral blood | Bone marrow | Remission | Acute myeloid leukemia | Cancer
Journal Article
JAMA, ISSN 0098-7484, 12/2015, Volume 314, Issue 23, pp. 2524 - 2534
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 10/2013, Volume 31, Issue 28, pp. 3549 - 3549
Journal Article
Leukemia, ISSN 0887-6924, 01/2019, Volume 33, Issue 1, pp. 230 - 239
Haploidentical stem cell transplantation with T cell-replete grafts and post-transplant cyclophosphamide (PTCy) is increasingly used with encouraging outcome.... 
IMPACT | ONCOLOGY | DONOR | BONE-MARROW-TRANSPLANTATION | GRAFT | ACUTE MYELOID-LEUKEMIA | HEMATOLOGY | HEMATOPOIETIC TRANSPLANTATION | RECONSTITUTION | T-CELLS | CLINICAL-OUTCOMES | BLOOD | Graft vs Host Disease - therapy | Precursor Cell Lymphoblastic Leukemia-Lymphoma - immunology | Prognosis | Follow-Up Studies | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Male | Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality | Leukemia, Myeloid, Acute - immunology | Hematopoietic Stem Cell Transplantation - mortality | Graft vs Host Disease - immunology | Cyclophosphamide - therapeutic use | Young Adult | Graft vs Host Disease - genetics | Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy | Graft vs Host Disease - mortality | Killer Cells, Natural - immunology | Adult | Female | Retrospective Studies | Leukemia, Myeloid, Acute - therapy | Receptors, KIR - genetics | Survival Rate | Leukemia, Myeloid, Acute - mortality | Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics | Aged | Transplantation Conditioning | Transplantation, Haploidentical | Histocompatibility | Receptors, KIR - immunology | Leukemia, Myeloid, Acute - genetics | Graft-versus-host reaction | Transplants & implants | Leukemia | Stem cell transplantation | Transplantation | Lymphocytes T | Multivariate analysis | Confidence intervals | Lymphocytes | Peripheral blood | Killer cell immunoglobulin-like receptors | Bone marrow | Remission | Natural killer cells | Immunoglobulins | Acute lymphatic leukemia | Myeloid leukemia | Transplants | Lymphatic leukemia | Survival | Patients | Cyclophosphamide | Grafts | Stem cells | Ligands | Acute myeloid leukemia
Journal Article
British Journal of Haematology, ISSN 0007-1048, 02/2017, Volume 176, Issue 3, pp. 431 - 439
Summary This study analysed the outcome of 267 patients with relapse/refractory acute myeloid leukaemia (AML) who received sequential chemotherapy including... 
sequential chemotherapy | reduced intensity conditioning | acute myeloid leukaemia | allogeneic haematopoietic stem cell transplantation | CYTOSINE-ARABINOSIDE | FREE SURVIVAL | BONE-MARROW-TRANSPLANTATION | 1ST COMPLETE REMISSION | MYELODYSPLASTIC SYNDROME | MATCHED UNRELATED DONORS | GRAFT-VERSUS-LEUKEMIA | HIGH-RISK | HLA-IDENTICAL SIBLINGS | HOST-DISEASE | HEMATOLOGY | Recurrence | Humans | Middle Aged | Male | Hematopoietic Stem Cell Transplantation - mortality | Leukemia, Myeloid, Acute - complications | Young Adult | Allografts | Hematopoietic Stem Cell Transplantation - adverse effects | Adult | Female | Surveys and Questionnaires | Retrospective Studies | Transplantation Conditioning - methods | Graft vs Host Disease - etiology | Leukemia, Myeloid, Acute - therapy | Antibodies - therapeutic use | Survival Rate | Treatment Outcome | Combined Modality Therapy | Leukemia, Myeloid, Acute - mortality | Antibodies - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | T-Lymphocytes - immunology | Aged | Hematopoietic Stem Cell Transplantation - methods | Salvage Therapy - methods | Surveys | Viral antibodies | Chemotherapy | Relapse | Stem cells | Antibodies | Transplantation | T cells | Hematopoietic stem cells | Diseases | Cancer | Graft-versus-host reaction | Immunoglobulins | Transplants & implants | Leukemia | Stem cell transplantation | Transplants | Lymphocytes T | Multivariate analysis | Patients | Survival | Incidence | Cytarabine | Fludarabine | Donors | Conditioning
Journal Article